BEIJING – China is using AbbVie Inc.’s HIV drugs as an ad-hoc treatment for pneumonia caused by the novel coronavirus while the global search for a cure continues.
The Beijing branch of China’s National Health Commission said that a combination of lopinavir and ritonavir, sold under the brand name Kaletra by AbbVie, is part of its latest treatment plan for patients infected by the virus, which has killed at least 56 people in China and sickened more than 2,000 worldwide.
The NHC said that while there is not yet any effective anti-viral drug, it recommends patients be given two lopinavir and ritonavir tablets twice a day and a dose of alpha-interpheron through nebulization twice daily.
Medical journal Lancet said on Friday that a clinical trial is under way using ritonavir and lopinavir to treat cases of the new coronavirus.
In the meantime, China’s Center for Disease Control and Prevention will start developing a vaccine, according to the Global Times.
Wang Guangfa, a respiratory expert at Peking University First Hospital in Beijing who was infected by the virus after visiting Wuhan to inspect coronavirus patients, told China News Week earlier this week that his doctor recommended he take the HIV drugs to fight the new virus and they worked on him.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.